Navigation Links
Updated Clinical Results Show Experimental Agent Ibrutinib as Highly Active in CLL Patients
Date:12/8/2012

COLUMBUS, Ohio Updated results from a Phase Ib/II clinical trial indicates that a novel therapeutic agent for chronic lymphocytic leukemia (CLL) is highly active and well tolerated in patients who have relapsed and are resistant to other therapy.

The agent, ibrutinib (PCI-32765), is the first drug designed to target Bruton's tyrosine kinase (BTK), a protein essential for CLL-cell survival and proliferation. CLL is the most common form of leukemia, with about 15,000 new cases annually in the U.S. About 4,400 Americans die of the disease each year.

Study co-leader Dr. John C. Byrd, director of the division of hematology at Ohio State University Comprehensive Cancer Center Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC James) presented these findings today (12/8) at the 54th Annual Meeting of the American Society of Hematology (ASH) Annual Meeting in Atlanta, GA.

The study found that response to therapy was high across cohorts, with 71 percent of previously untreated older patients experiencing a complete or partial response at either treatment dose (420mg and 840mg). The same response was observed in 67 percent of the relapsed patients and half (50%) of the high-risk patient cohort. After 22 months of follow-up, the disease had not progressed in 96 percent of previously untreated patients and 76 percent of relapsed and high-risk patients.

"These findings are truly exciting because they demonstrate ibrutinib's potential as a highly active, well-tolerated first-line therapy for CLL that produces a high rate of durable remissions the remissions last months on end," Byrd says. "The drug is effective in part because patients are willing to stay on treatment since the side effects are very tolerable," he states.

Only non-severe side effects, including diarrhea, fatigue, chest infection, rash, nausea, joint pain and infrequent and transient low blood counts were observed. Investigators found no evidence of c
'/>"/>

Contact: Liz Bryan, Spectrum
lbryan@spectrumscience.com
443-506-1931
Ohio State University Medical Center
Source:Eurekalert

Page: 1 2

Related medicine news :

1. EzCheckPrinting Updated with New Category Feature to Simplify Check Printing and Tax Reporting
2. Winning the battle against leukaemia: Positive early results in clinical trial for DNA vaccine
3. Pure Cocoa Powder, the Key Ingredient in Dark Chocolate and Found in Diabetes Support Supplements has been Clinically Proven to Reduce Cardiovascular Risk
4. USC Norris cancer research ranks among top clinical advances for 2012
5. American Society of Clinical Oncology issues annual report on state of clinical cancer science
6. Clinical trial at GHSU Cancer Center targets advanced prostate cancer
7. Study finds link between access to online health information and use of clinical services
8. Edison Pharmaceuticals announces initiation of EPI-743 Phase 2B Leigh Syndrome Clinical Trial
9. Molecular portraits of tumours match patients with trials in everyday clinical practice
10. New targeted therapy for advanced prostate cancer shows anti-tumor activity in clinical trials
11. Spread of human melanoma cells in mice correlates with clinical outcomes in patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... On Saturday, September 6, 2014, The Concilio will present its ... Get Up! Get Moving!®. This event promotes Hispanic family physical ... people of all ages and all sizes. The event, which ... at Kiest Park Recreation Center, 3080 S. Hampton Road, in ... 2007, we have partnered with National Alliance for Hispanic Health ...
(Date:9/2/2014)... September 02, 2014 West Hollywood ... complimentary consultations for Invisalign. This special offer includes a ... smiles to determine their candidacy for the procedure and ... Qualified patients may also be eligible for the Summer ... remainder of the month of August, patients who choose ...
(Date:9/2/2014)... 1, 2014 (HealthDay News) -- The quality of Americans, ... dietary disparity between the rich and poor is growing, ... most direct evidence to date that the extensive efforts ... quality are having some payoff, but it also indicates ... Dong Wang, a doctoral student in the department of ...
(Date:9/2/2014)... it comes to excess pounds and blood pressure, all fat ... The research found that belly fat -- the proverbial "spare ... more than overall body fat. It,s well known that ... wasn,t clear how the location of fat in the body ... Southwestern Medical Center in Dallas. Reporting Sept. 1 in ...
(Date:9/2/2014)... (PRWEB) September 02, 2014 North ... America Resectoscopes Market Outlook to 2020? provides key ... The report provides value, in millions of US ... US dollars) within market segments –, ... (Disposable and Reusable) Electrodes and Bipolar (Disposable and ...
Breaking Medicine News(10 mins):Health News:The Concilio Presents Eighth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 2Health News:The Concilio Presents Eighth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 3Health News:The Concilio Presents Eighth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 4Health News:West Hollywood Cosmetic Dentist, Dr. Poneh Ghasri, Now Offers Complimentary Consultations for Invisalign 2Health News:Quality of U.S. Diet Improves, Slightly 2Health News:'Spare Tire' May Be Especially Bad for Your Blood Pressure 2Health News:North America Resectoscopes & Bronchoscopes Market (Revenue, Volume & Company Share) to 2020 Report Available at MarketOptimizer.org 2Health News:North America Resectoscopes & Bronchoscopes Market (Revenue, Volume & Company Share) to 2020 Report Available at MarketOptimizer.org 3Health News:North America Resectoscopes & Bronchoscopes Market (Revenue, Volume & Company Share) to 2020 Report Available at MarketOptimizer.org 4
... Legislation Introduced to Fund Lung Cancer ResearchBOSTON, Jan. ... Senator Susan Fargo (D-3rd Middlesex), the Senate Chair ... once again introducing comprehensive legislation that creates a ... http://www.newscom.com/cgi-bin/prnh/20081016/LCALOGO )"Now is the time for positive ...
... (Nasdaq: ROCM ) today announced that Covidien ... litigation which Rochester Medical,filed on March 16, 2004 against ... L.P.; Novation, LLC; VHA Inc.; and Premier Purchasing,Partners L.P. ... of the settlement, Rochester Medical, represented by The,Lanier Law ...
... festival in Park,City, Utah, usually known for power lunches, will ... full-service fitness center, called,the "G Gym." Actors Eliza Dushku ... of the many celebrities to snatch up appointments with top,Hollywood ... or $1,000 for,charity, up to $20,000. , ...
... YORK, Jan. 15 On Tuesday, February 3, 2009, ... The Fifth Annual Beyond Beauty Gala to benefit The ... genetic research and awareness for Obsessive-Compulsive Disorder (OCD). ... evening,s event will be held at The Union League ...
... Package and House Vote to Expand Child Health InsuranceTUCSON, Ariz., ... Corporation (Nasdaq: PRSC ) today provided an update ... package being sought by President-elect Barack Obama as well as ... insurance. The economic stimulus package under discussion includes aid ...
... Roxane Laboratories, Inc.,announced today the approval of their ... 500mg, 750mg, 1000mg, and Oral Solution,100mg/mL. The product ... nationwide. , Roxane Laboratories, ... UCB, Inc.,s KEPPRA(R) (levetiracetam). Annual sales of KEPPRA(R) ...
Cached Medicine News:Health News:Lung Cancer Alliance Hails Massachusetts State Senator for Taking Lead on Lung Cancer 2Health News:Celebrities Stay Fit at First Ever Full-Service Luxury Gym at Film Festival in Park City, Utah 2Health News:Legendary Folk Icon, Judy Collins, to Perform at The Fifth Annual James E. Marshall OCD Foundation Beyond Beauty Gala 2Health News:Legendary Folk Icon, Judy Collins, to Perform at The Fifth Annual James E. Marshall OCD Foundation Beyond Beauty Gala 3Health News:Providence Service Corporation Provides Update on Potential Medicaid 2Health News:Providence Service Corporation Provides Update on Potential Medicaid 3Health News:Roxane Laboratories, Inc. Announces the Launch of Levetiracetam Tablets and Oral Solution 2
(Date:9/2/2014)... , Sept. 2, 2014  Drug delivery technologies that ... essential part of the entire drug development process. ... in new vaccine delivery technologies in a bid ... skin delivery procedures. New analysis from ... though the needle-free delivery sector currently makes up ...
(Date:9/2/2014)... COSTA MESA, Calif. , Sept. 2, 2014 ... organization was just recognized as one of the ... Over the past few years, the company has ... phase clinical research, late phase global clinical development, ... the past 2 years, WCCT Global has successfully ...
(Date:9/1/2014)... YORK , Sept. 1, 2014 ... market research report is available in its catalogue: ... 2014 - 2024 http://www.reportlinker.com/p02280919/Antibody-Drug-Conjugates-Market-2nd-Edition-2014---2024.html ... (ADCs) are a new class of therapeutic agents, ... pharmaceutical companies. Generally addressed as the marriage of ...
Breaking Medicine Technology:Needle-Free Delivery Devices Shape the Future of Vaccines, Says Frost & Sullivan 2Needle-Free Delivery Devices Shape the Future of Vaccines, Says Frost & Sullivan 3Contract Research Organization WCCT Global Celebrates Being Named as One of the Fastest Growing Companies in America 2Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 2Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 3Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 4Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 5Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 6Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 7Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 8Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 9Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 10Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 11Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 12Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 13Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 14Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 15Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 16Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 17Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 18
... USCAP MeetingSOUTH SAN FRANCISCO, Calif., March 13 Rigel ... the enrollment of the first patient in a Phase ... patients with refractory or relapsed peripheral T-cell lymphoma (PTCL). ... the efficacy of R788, an orally bio-available Syk kinase ...
... Phase II Study Published in The Lancet of Fast-Tracked ... Minor Bleeding and was Well Tolerated When Given With ... a Schering-Plough Corporation (NYSE: SGP ) Phase ... receptor antagonist (TRA), were published today in The ...
Cached Medicine Technology:Rigel Commences Phase 2 Trial of R788 in Peripheral T-Cell Lymphomas 2Rigel Commences Phase 2 Trial of R788 in Peripheral T-Cell Lymphomas 3Schering-Plough's Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study 2Schering-Plough's Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study 3Schering-Plough's Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study 4Schering-Plough's Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study 5Schering-Plough's Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study 6Schering-Plough's Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study 7
... The Finnpipette BioControl multichannel ... as the single channel model. ... all seven multichannel and five ... Both pipettes have a recharge ...
... solution and best value in high performance ... and ultra lightweight design reduce hand fatigue ... long, lever tip ejector , Color coding ... tips or for greater performance use Hamilton ...
... Pipette is ideal for all liquid handling ... ergonomically-placed operating buttons, and various dispensing techniques ... diluting make this a lab favorite. It ... manual pipette without any adverse effects on ...
... Unparalleled Comfort Pick one of our pipettors ... the trigger and ejector positionsright where they should ... are ergonomically designed to help avoid repetitive stress ... Productivity In The Palm Of Your Hand ...
Medicine Products: